Nachrichten zur Xenon Pharmaceuticals Inc. Aktie

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON),…

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN)…

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced…

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Researchs Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…

Algernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltx

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has finalized the acquisition of its NP-120 (Ifenprodil) research program by US-based Seyltx Inc in…

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON),…

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

…

Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript

…

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial Setbacks

…

Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Algernon Pharmaceuticals Announces Closing of Private Placement

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the…

Algernon Pharmaceuticals Announces Increase to Private Placement

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the…

Algernon Pharmaceuticals Announces Private Placement

VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the…

Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN)…

Xenon Pharmaceuticals prices upsized $300.0 million securities offering

…

Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering

VANCOUVER, British Columbia, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE) (“Xenon”), a neurology-focused biopharmaceutical company,…

: Xenon Pharmaceuticals’ stock falls as depression treatment has mixed results in clinical trial

Xenon Pharmaceuticals shares fell early Monday after the company released new clinical-trial data on an experimental depression treatment.…

Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip

…

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…

Eton Pharmaceuticals, Inc. (ETON) Q3 2023 Earnings Call Transcript

…

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON),…

Xenon Pharmaceuticals Inc. (XENE) Q3 2023 Earnings Call Transcript

…

Xenon Pharmaceuticals: Upcoming Phase Two Major Depressive Disorder Data Readout Represents An Opportunity

…

Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology

VANCOUVER, British Columbia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today…

Prostate Health Market Size to Hit $ 82.64 Bn by 2032 | Rapid Advancements & Innovation in Prostate Health Treatments

[230+ Pages Report] According to a market research study published by The Brainy Insights, the demand analysis of Global…

Specialty Generics Market to Reach USD 184.8 Billion by 2032; Increasing Capacity for Walking & Physical Activities to Propel Growth, says The Brainy Insights

Global specialty generics market size from USD 70.0 billion in 2022 to USD 184.8 billion, growing at a CAGR of…

Anti-snoring Devices and Snoring Surgery Market to Reach USD 3.90 Billion by 2032; Growing Preference for Non-Invasive Treatments to Propel Growth

Anti-snoring devices and snoring surgery market size is anticipated to grow from USD 1.73 Billion to USD 3.90 Billion in…

dpa-AFX ProFeed